Weifa AS-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Weifa AS - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013203
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:16
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ノルウェー
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Weifa AS (Weifa), a subsidiary of Weifa ASA, is a healthcare solution provider that research, develops, produces, distributes and sells medicines, and lifestyle products. The company’s products comprise Tylenol, paracetduo, ibux, ibux gel, tiger balm, proxan, nazareth, dexyl, tussin, bronkyl, pyrisept, codfish, pyrivir cold sore gel, weifa-kalcium dietary supplement, weifa-c rose hip extract, fluormax, ferromax and samin. Weifa produces active pharmaceutical ingredients and finished products. The company operates in Germany, the UK, Eastern Europe, Africa, North America, South America and Asia. Weifa is headquartered in Oslo, Norway.

Weifa AS – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Weifa AS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Weifa AS, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Weifa AS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Weifa AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Weifa AS, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Weifa AS, Pharmaceuticals & Healthcare, Deal Details 10
Equity Offering 10
Weifa Raises USD18 Million in Private Placement of Shares 10
Weifa to Raise USD16.3 Million in Rights Offering of Shares 11
Acquisition 12
Aqualis Completes Acquisition of Weifa for USD183.6 Million 12
Weifa AS – Key Competitors 13
Weifa AS – Key Employees 14
Weifa AS – Locations And Subsidiaries 15
Head Office 15
Appendix 16
Methodology 16
About GlobalData 16
Contact Us 16
Disclaimer 16

List of Tables
Weifa AS, Pharmaceuticals & Healthcare, Key Facts 2
Weifa AS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Weifa AS, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Weifa AS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Weifa AS, Deals By Therapy Area, 2011 to YTD 2017 8
Weifa AS, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Weifa Raises USD18 Million in Private Placement of Shares 10
Weifa to Raise USD16.3 Million in Rights Offering of Shares 11
Aqualis Completes Acquisition of Weifa for USD183.6 Million 12
Weifa AS, Key Competitors 13
Weifa AS, Key Employees 14

★海外企業調査レポート[Weifa AS-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • The Emirates Group:企業の戦略・SWOT・財務情報
    The Emirates Group - Strategy, SWOT and Corporate Finance Report Summary The Emirates Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • TDC AS:企業の戦略的SWOT分析
    TDC AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • PerkinElmer Inc (PKI):企業の財務・戦略的SWOT分析
    PerkinElmer Inc (PKI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • The Lubrizol Corporation-製薬・医療分野:企業M&A・提携分析
    Summary The Lubrizol Corporation (Lubrizol), a subsidiary of Berkshire Hathaway Inc., is a specialty chemical company that produces and supplies technologies to the global transportation, industrial, and consumer markets. Its products and services include engine additives, driveline additives, indus …
  • MediWound Ltd (MDWD):製薬・医療:M&Aディール及び事業提携情報
    Summary MediWound Ltd (MediWound) is a biopharmaceutical company that on develops, manufactures and commercializes novel therapeutics based on its patented proteolytic enzyme technology. Its products address unmet needs in the areas of severe burns, chronic and other hard-to-heal wounds.The company’ …
  • Oncolix Inc (ONCX):製薬・医療:M&Aディール及び事業提携情報
    Summary Oncolix Inc (Oncolix) is a clinical stage biotechnology company. It is developing a targeted therapeutic protein, Prolanta for the treatment of ovarian, breast and other cancers. Prolanta is a recombinant analogue to the human prolactin and acts as an antagonist to the prolactin receptor. On …
  • Shenzhen Kaifa Technology Co Ltd (000021):企業の財務・戦略的SWOT分析
    Shenzhen Kaifa Technology Co Ltd (000021) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Syros Pharmaceuticals Inc (SYRS):医療機器:M&Aディール及び事業提携情報
    Summary Syros Pharmaceuticals Inc (Syros) is a biopharmaceutical company that develops medicines for the treatment of cancer, immune-mediated diseases, and other diseases. The company’s pipeline products under clinical trials include SY-1425, an oral, potent and selective RARa agonist that is used t …
  • BrightSpring Health Services:企業の戦略的SWOT分析
    BrightSpring Health Services - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Marr S.P.A.
    Marr S.P.A. - Strategy, SWOT and Corporate Finance Report Summary Marr S.P.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • CMC Biologics AS:製薬・医療:M&Aディール及び事業提携情報
    Summary CMC Biologics A/S (CMC Biologics), formerly CMC Biopharmaceuticals A/S, a subsidiary of Asahi Glass Co., Ltd., is a contract process development and manufacturer of biopharmaceuticals. The company's service portfolio encompasses process development, cGMP manufacturing, and quality and regula …
  • CIC Insurance Group Limited (CIC):企業の財務・戦略的SWOT分析
    CIC Insurance Group Limited (CIC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • The Kansai Electric Power Co Inc (9503):電力:M&Aディール及び事業提携情報
    Summary The Kansai Electric Power Co Inc (KEPCo) is an integrated power utility. It produces and supplies electricity and thermal energy; and procures and sells natural gas. The company generates electricity using natural gas, nuclear, coal, oil, wind, hydro, and solar sources. Through long, medium, …
  • Acura Pharmaceuticals Inc (ACUR):製薬・医療:M&Aディール及び事業提携情報
    Summary Acura Pharmaceuticals Inc (Acura) is a specialty pharmaceutical company that researches, develops, and commercializes tamper-resistant products to prevent the abuse and misuse of medication. The company’s proprietary technologies, Aversion, Limitx and Impede, are used to prevent product tamp …
  • Jardine Engineering Corporation, Limited:企業の戦略・SWOT・財務情報
    Jardine Engineering Corporation, Limited - Strategy, SWOT and Corporate Finance Report Summary Jardine Engineering Corporation, Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Saft Groupe SA:企業の戦略的SWOT分析
    Saft Groupe SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Z Energy Ltd:企業の戦略・SWOT・財務分析
    Z Energy Ltd - Strategy, SWOT and Corporate Finance Report Summary Z Energy Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • The Bangchak Petroleum PCL (BCP):石油・ガス:M&Aディール及び事業提携情報
    Summary The Bangchak Petroleum PCL (Bangchak) is an oil and gas company. It carries out import of crude oil from both indigenous and overseas sources, and refines it into finished petroleum products. Its refinery produces gasoline, gasohol and diesel products. The company markets its petroleum produ …
  • Robert Half International Inc. (RHI):企業の財務・戦略的SWOT分析
    Robert Half International Inc. (RHI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • McDermott International Inc (MDR):企業の財務・戦略的SWOT分析
    McDermott International Inc (MDR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆